Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Organogenesis ORG -- Ignore unavailable to you. Want to Upgrade?

To: Link Lady who wrote (1183)	2/8/1999 12:32:00 PM
From: Link Lady	Read Replies (1) \| Respond to of 1223

Does anyone have any idea which companies have been involved in Canada regarding Diabetic Foot Ulcers? newswire.ca Attention News/Health Editors: MEDIA ADVISORY - Wound care specialists to discuss groundbreaking biotechnology drug for treatment of diabetic foot ulcers TORONTO, Feb. 8 /CNW/ - Diabetic foot ulcers are one of the most alarming complications associated with diabetes, risking severe infection, gangrene, amputation and even death. In fact, diabetic foot ulcers precede 85 per cent of all amputations in patients with diabetes and account for more hospital days than all other diabetic complications combined. Both patient quality of life and the health care system suffer dreadfully from these chronic wounds. Please plan to attend this media conference where wound care and diabetes experts discuss the seriousness of diabetic foot ulcers and the availability of the first active biotechnology wound healing therapeutic. Hear a Canadian ulcer sufferer's story, and the hope this breakthrough drug has brought him for a return to an acceptable quality of life. WHAT: First Active Wound Healing Drug Approved for Use in Canada Wound care specialists to discuss groundbreaking biotechnology drug for treatment of diabetic foot ulcers WHO: Dr. John Embil, Co-ordinator, Diabetic Foot and Complicated Wound Clinic, Health Sciences Centre, Winnipeg Dr. Gordon Dow, Infectious Disease Specialist, Moncton Hospital Carol Seto, Director, Public Education, Canadian Diabetes Association Terry Oraschuk, diabetic foot ulcer sufferer Ann Humphreys, Vice President of Biotechnology and New Product Development, Janssen-Ortho Inc. WHEN: Thursday, February 11th, 1999 10:00 a.m. to 11:00 a.m. WHERE: The King Edward Meridian Belgravia Room -30- For further information: Krista Webster/Deborah Etsten/Julie Hoernig, Lexicomm Communications, (416) 368-0208